Get the Stockscreener App
1.15
2.54%
-0.03
Zura Bio Ltd stock is traded at $1.15, with a volume of 242.90K.
It is down -2.54% in the last 24 hours and up +12.75% over the past month.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
See More
Previous Close:
$1.18
Open:
$1.17
24h Volume:
242.90K
Relative Volume:
0.53
Market Cap:
$79.20M
Revenue:
-
Net Income/Loss:
$-60.36M
P/E Ratio:
-0.2617
EPS:
-4.394
Net Cash Flow:
$-15.05M
1W Performance:
+3.60%
1M Performance:
+12.75%
6M Performance:
-56.93%
1Y Performance:
-64.83%
1-Day Range:
$1.115
$1.1997
1-Week Range:
$1.10
$1.22
52-Week Range:
$0.97
$5.07
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.15 | 79.20M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Two Sigma Investments LP Decreases Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Analysts Set Expectations for Zura Bio FY2026 Earnings - Defense World
Squarepoint Ops LLC Cuts Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA Announces Upcoming Conference Call Hosted by Piper Sandler - GuruFocus
Two Sigma Advisers LP Invests $32,000 in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Northern Trust Corp Has $1.01 Million Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Consensus Target Price from Analysts - Defense World
Zura Bio to Present at the Jefferies Global Healthcare Conference - Yahoo Finance
Zura Bio shareholders approve board nominees and auditor - Investing.com Australia
Zura Bio shareholders approve board nominees and auditor By Investing.com - Investing.com South Africa
Q1 Earnings Forecast for Zura Bio Issued By HC Wainwright - Defense World
Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa - Clinical Trials Arena
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment - Investing.com Australia
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment By Investing.com - Investing.com India
Zura Bio (ZURA) Initiates Phase 2 Study for Tibulizumab in HS Treatment | ZURA Stock News - GuruFocus
Cubist Systematic Strategies LLC Makes New $62,000 Investment in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa - Quantisnow
Zura Bio (ZURA) Initiates Phase 2 Study for Tibulizumab in HS Tr - GuruFocus
Dimensional Fund Advisors LP Acquires New Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Wells Fargo & Company MN Grows Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Barclays PLC Boosts Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Raymond James Financial Inc. Invests $371,000 in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $17.00 - Defense World
ZURA Stock Rating Maintained; Price Target Lowered by Oppenheime - GuruFocus
ZURA: Oppenheimer Revises Price Target Amid Ongoing Trials | ZUR - GuruFocus
ZURA Stock Rating Maintained; Price Target Lowered by Oppenheimer | ZURA Stock News - GuruFocus
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates - Yahoo Finance
Ratio Analysis: Unpacking Zura Bio Ltd (ZURA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Zura Bio Ltd Inc. (ZURA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Do investors need to be concerned about Zura Bio Ltd (ZURA)? - uspostnews.com
Geode Capital Management LLC Increases Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Yahoo
ZURA overperforms with a 8.76 increase in share price - uspostnews.com
Zura Bio Limited (NASDAQ:ZURA) Receives $14.67 Average Price Target from Analysts - Defense World
HC Wainwright Has Negative Estimate for Zura Bio Q1 Earnings - Defense World
HC Wainwright Lowers Zura Bio (NASDAQ:ZURA) Price Target to $3.00 - Defense World
ZURA stock touches 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating - Investing.com Australia
ZURA stock touches 52-week low at $1.07 amid market challenges - Investing.com
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating By Investing.com - Investing.com South Africa
Insiders' US$1.01m Investments In Red Following Zura Bio's US$21m Dip In Market Value - simplywall.st
Cantor Fitzgerald Forecasts Weaker Earnings for Zura Bio - Defense World
Zura Bio (NASDAQ:ZURA) Price Target Lowered to $10.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Chardan cuts Zura Bio stock target to $10, keeps buy rating By Investing.com - Investing.com South Africa
Chardan cuts Zura Bio stock target to $10, keeps buy rating - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target By Investing.com - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target - Investing.com
Leerink maintains $12 target on Zura Bio stock post-earnings By Investing.com - Investing.com Australia
Leerink maintains $12 target on Zura Bio stock post-earnings - Investing.com
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zura Bio Ltd Stock (ZURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thiara Parvinder | Director |
Sep 11 '24 |
Sale |
2.70 |
3,800,000 |
10,260,000 |
1,001,633 |
| Sidhu Someit | Director |
Sep 04 '24 |
Sale |
3.87 |
51,728 |
200,187 |
2,085,418 |
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):